



## **For Immediate Release**

Date: February 1, 2017

Contact: Thomas A. Schreck, Vice-Chairman

Phone: (650) 714-0445

## **SinuSys™ Corporation hires Bill Mavity as President & CEO**

**Palo Alto, Calif.** - February 1, 2017 - SinuSys Corporation today announced the appointment of William G. (“Bill”) Mavity as the Company’s President and Chief Executive Officer. Co-founder Tom Schreck will assume the position of Vice-Chairman of the Board of Directors, and will continue to provide guidance to the drug delivery development program aimed at the controlled delivery of specific drugs to human tissues, leveraging the Company’s proprietary osmotic expansion capability that has been advanced under his leadership.

In commenting on the new opportunity, Mr. Mavity noted “I am very much looking forward to joining SinuSys and helping to expand commercialization of the Vent-Os family of products for the dilation of sinus passages in the treatment of chronic sinusitis. These products have the potential to alter the treatment regimen for millions of patients by allowing delivery, in the office environment, of a minimally invasive solution that has already generated positive outcomes in hundreds of treated patients. The gentle dilation of tissues over an approximate one-hour period in the office represents a new paradigm that can offer substantial benefits for patients, caregivers, and payers.”

“I am also very excited about the longer-term potential offered by the Company’s drug delivery program. This development effort is intended to provide an improved means of delivering appropriate medications to human tissues, and may have applicability both in ENT procedures, and other applications where controlled drug delivery over extended periods offers enhanced treatment options. Recent in vivo and bench testing has confirmed that a near-steady rate of delivery over a period of more than one week is feasible.”

## **About the SinuSys Corporation**

SinuSys Corp. ([www.sinusys.com](http://www.sinusys.com)) strives to improve the health of patients worldwide through the commercialization of the Vent-Os Sinus Dilation Systems, the development of drug delivery product candidates, and other osmotic and rate controlled technologies to treat serious ear, nose, and throat conditions. The company’s proprietary technologies are designed to be atraumatic, tissue sparing, and easy to administer, potentially enabling clinicians to intervene at early stages of sinus disease.

###